Anita L Grubb1, Timothy J McDonald1,2, Femke Rutters3, Louise A Donnelly4, Andrew T Hattersley1,2, Richard A Oram1,2, Colin N A Palmer4, Amber A van der Heijden5, Fiona Carr4, Petra J M Elders5, Mike N Weedon1, Roderick C Slieker3,6, Leen M 't Hart3,6,7, Ewan R Pearson4, Beverley M Shields1, Angus G Jones8,2. 1. National Institute for Health Research Exeter Clinical Research Facility, University of Exeter Medical School, Exeter, U.K. 2. Royal Devon and Exeter NHS Foundation Trust, Exeter, U.K. 3. Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, the Netherlands. 4. Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, U.K. 5. Department of General Practice and Elderly Care Medicine, Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, the Netherlands. 6. Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands. 7. Molecular Epidemiology, Leiden University Medical Center, Leiden, the Netherlands. 8. National Institute for Health Research Exeter Clinical Research Facility, University of Exeter Medical School, Exeter, U.K. angus.jones@exeter.ac.uk.
Abstract
OBJECTIVE: Progression to insulin therapy in clinically diagnosed type 2 diabetes is highly variable. GAD65 autoantibodies (GADA) are associated with faster progression, but their predictive value is limited. We aimed to determine if a type 1 diabetes genetic risk score (T1D GRS) could predict rapid progression to insulin treatment over and above GADA testing. RESEARCH DESIGN AND METHODS: We examined the relationship between T1D GRS, GADA (negative or positive), and rapid insulin requirement (within 5 years) using Kaplan-Meier survival analysis and Cox regression in 8,608 participants with clinical type 2 diabetes (onset >35 years and treated without insulin for ≥6 months). T1D GRS was both analyzed continuously (as standardized scores) and categorized based on previously reported centiles of a population with type 1 diabetes (<5th [low], 5th-50th [medium], and >50th [high]). RESULTS: In GADA-positive participants (3.3%), those with higher T1D GRS progressed to insulin more quickly: probability of insulin requirement at 5 years (95% CI): 47.9% (35.0%, 62.78%) (high T1D GRS) vs. 27.6% (20.5%, 36.5%) (medium T1D GRS) vs. 17.6% (11.2%, 27.2%) (low T1D GRS); P = 0.001. In contrast, T1D GRS did not predict rapid insulin requirement in GADA-negative participants (P = 0.4). In Cox regression analysis with adjustment for age of diagnosis, BMI, and cohort, T1D GRS was independently associated with time to insulin only in the presence of GADA: hazard ratio per SD increase was 1.48 (1.15, 1.90); P = 0.002. CONCLUSIONS: A T1D GRS alters the clinical implications of a positive GADA test in patients with clinical type 2 diabetes and is independent of and additive to clinical features.
OBJECTIVE: Progression to insulin therapy in clinically diagnosed type 2 diabetes is highly variable. GAD65 autoantibodies (GADA) are associated with faster progression, but their predictive value is limited. We aimed to determine if a type 1 diabetes genetic risk score (T1D GRS) could predict rapid progression to insulin treatment over and above GADA testing. RESEARCH DESIGN AND METHODS: We examined the relationship between T1D GRS, GADA (negative or positive), and rapid insulin requirement (within 5 years) using Kaplan-Meier survival analysis and Cox regression in 8,608 participants with clinical type 2 diabetes (onset >35 years and treated without insulin for ≥6 months). T1D GRS was both analyzed continuously (as standardized scores) and categorized based on previously reported centiles of a population with type 1 diabetes (<5th [low], 5th-50th [medium], and >50th [high]). RESULTS: In GADA-positive participants (3.3%), those with higher T1D GRS progressed to insulin more quickly: probability of insulin requirement at 5 years (95% CI): 47.9% (35.0%, 62.78%) (high T1D GRS) vs. 27.6% (20.5%, 36.5%) (medium T1D GRS) vs. 17.6% (11.2%, 27.2%) (low T1D GRS); P = 0.001. In contrast, T1D GRS did not predict rapid insulin requirement in GADA-negative participants (P = 0.4). In Cox regression analysis with adjustment for age of diagnosis, BMI, and cohort, T1D GRS was independently associated with time to insulin only in the presence of GADA: hazard ratio per SD increase was 1.48 (1.15, 1.90); P = 0.002. CONCLUSIONS: A T1D GRS alters the clinical implications of a positive GADA test in patients with clinical type 2 diabetes and is independent of and additive to clinical features.
Authors: M N Weedon; A T Hattersley; K A Patel; R A Oram; S E Flanagan; E De Franco; K Colclough; M Shepherd; S Ellard Journal: Diabetes Date: 2016-04-05 Impact factor: 9.461
Authors: Melis A Aksit; Rhonda G Pace; Briana Vecchio-Pagán; Hua Ling; Johanna M Rommens; Pierre-Yves Boelle; Loic Guillot; Karen S Raraigh; Elizabeth Pugh; Peng Zhang; Lisa J Strug; Mitch L Drumm; Michael R Knowles; Garry R Cutting; Harriet Corvol; Scott M Blackman Journal: J Clin Endocrinol Metab Date: 2020-05-01 Impact factor: 5.958
Authors: Wendy K Chung; Karel Erion; Jose C Florez; Andrew T Hattersley; Marie-France Hivert; Christine G Lee; Mark I McCarthy; John J Nolan; Jill M Norris; Ewan R Pearson; Louis Philipson; Allison T McElvaine; William T Cefalu; Stephen S Rich; Paul W Franks Journal: Diabetologia Date: 2020-09 Impact factor: 10.122
Authors: Angus G Jones; Timothy J McDonald; Beverley M Shields; William Hagopian; Andrew T Hattersley Journal: Diabetes Care Date: 2021-05-20 Impact factor: 17.152
Authors: Nicholas J Thomas; Anita L Lynam; Anita V Hill; Michael N Weedon; Beverley M Shields; Richard A Oram; Timothy J McDonald; Andrew T Hattersley; Angus G Jones Journal: Diabetologia Date: 2019-04-10 Impact factor: 10.122